Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude P Muller

Showing results (1-10 of 223) with videos related to

Pageof 23
Sort By:
The Lancet Regional Health. Europe|May 17, 2021
Do asymptomatic carriers of SARS-COV-2 transmit the virus?Claude P Muller
The Lancet Regional Health. Europe|May 24, 2021
Can integrated post-exposure vaccination against SARS-COV2 mitigate severe disease?Claude P Muller
Vaccine|October 25, 2003
Modelling measles re-emergence as a result of waning of immunity in vaccinated populationsJoël Mossong, Claude P Muller
Journal of Molecular Endocrinology|October 12, 2005
Structure of the glucocorticoid receptor (NR3C1) gene 5' untranslated region: identification, and tissue distribution of multiple new human exon 1Jonathan D Turner, Claude P Muller
Lancet (London, England)|January 10, 2009
Measles in Europe--there is room for improvementJacques R Kremer, Claude P Muller
Journal of Clinical Microbiology|September 1, 2016
Reply to "May Newly Defined Genotypes XVII and XVIII of Newcastle Disease Virus in Poultry from West and Central Africa Be Considered a Single Genotype (XVII)?"Chantal J Snoeck, Claude P Muller
Antiviral Research|April 6, 2012
EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivoLinda L Theisen, Claude P Muller
Clinical and Diagnostic Laboratory Immunology|May 10, 2005
Evaluation of commercial assay detecting specific immunoglobulin g in oral fluid for determining measles immunity in vaccineesJacques R Kremer, Claude P Muller
Vaccine|January 18, 2003
The rationale of a peptide-conjugate vaccine against measlesMike M Pütz, Claude P Muller
Vaccine|March 10, 2005
Immunopropylactic approaches against chemical carcinogenesisStefan S De Buck, Claude P Muller
Pageof 23

Showing results (1-10 of 223) with videos related to

Sort By:
Pageof 23
The Lancet Regional Health. Europe|May 17, 2021
Do asymptomatic carriers of SARS-COV-2 transmit the virus?Claude P Muller
The Lancet Regional Health. Europe|May 24, 2021
Can integrated post-exposure vaccination against SARS-COV2 mitigate severe disease?Claude P Muller
Vaccine|October 25, 2003
Modelling measles re-emergence as a result of waning of immunity in vaccinated populationsJoël Mossong, Claude P Muller
Journal of Molecular Endocrinology|October 12, 2005
Structure of the glucocorticoid receptor (NR3C1) gene 5' untranslated region: identification, and tissue distribution of multiple new human exon 1Jonathan D Turner, Claude P Muller
Lancet (London, England)|January 10, 2009
Measles in Europe--there is room for improvementJacques R Kremer, Claude P Muller
Journal of Clinical Microbiology|September 1, 2016
Reply to "May Newly Defined Genotypes XVII and XVIII of Newcastle Disease Virus in Poultry from West and Central Africa Be Considered a Single Genotype (XVII)?"Chantal J Snoeck, Claude P Muller
Antiviral Research|April 6, 2012
EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivoLinda L Theisen, Claude P Muller
Clinical and Diagnostic Laboratory Immunology|May 10, 2005
Evaluation of commercial assay detecting specific immunoglobulin g in oral fluid for determining measles immunity in vaccineesJacques R Kremer, Claude P Muller
Vaccine|January 18, 2003
The rationale of a peptide-conjugate vaccine against measlesMike M Pütz, Claude P Muller
Vaccine|March 10, 2005
Immunopropylactic approaches against chemical carcinogenesisStefan S De Buck, Claude P Muller
Pageof 23